Evidence map›Paper›PMID 34103612›Full record

ArticleScientific reports2021

HIV-1 sequences in lentiviral vector genomes can be substantially reduced without compromising transduction efficiency.

Helin Sertkaya, Mattia Ficarelli, Nathan P Sweeney, Hannah Parker, Conrad A Vink, Chad M Swanson

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Helin SertkayaDepartment of Infectious Diseases, King's College London, London, SE1 9RT, UK.
Mattia FicarelliDepartment of Infectious Diseases, King's College London, London, SE1 9RT, UK.
Nathan P SweeneyCell & Gene Therapy Platform, Medicinal Science and Technology, GSK, Stevenage, SG1 2NY, UK.
Hannah ParkerDepartment of Infectious Diseases, King's College London, London, SE1 9RT, UK.
Conrad A VinkCell & Gene Therapy Platform, Medicinal Science and Technology, GSK, Stevenage, SG1 2NY, UK. conrad.x.vink@gsk.com.
Chad M SwansonDepartment of Infectious Diseases, King's College London, London, SE1 9RT, UK. chad.swanson@kcl.ac.uk.
King's College London · GBAge UK · GB

Funding

Biotechnology and Biological Sciences Research Council BB/P504609/1Department of HealthMedical Research Council MR/M019756/1Medical Research Council MR/R50225X/1Medical Research Council MR/S000844/1
6 · The paper itself

Abstract

Many lentiviral vectors used for gene therapy are derived from HIV-1. An optimal vector genome would include only the viral sequences required for transduction efficiency and gene expression to minimize the amount of foreign sequence inserted into a patient's genome. However, it remains unclear whether all of the HIV-1 sequence in vector genomes is essential. To determine which viral sequences are required, we performed a systematic deletion analysis, which showed that most of the gag region and over 50% of the env region could be deleted. Because the splicing profile for lentiviral vectors is poorly characterized, we used long-read sequencing to determine canonical and cryptic splice site usage. Deleting specific regions of env sequence reduced the number of splicing events per transcript and increased the proportion of unspliced genomes. Finally, combining a large deletion in gag with repositioning the Rev-response element downstream of the 3' R to prevent its reverse transcription showed that 1201 nucleotides of HIV-1 sequence can be removed from the integrated vector genome without substantially compromising transduction efficiency. Overall, this allows the creation of lentiviral vector genomes that contain minimal HIV-1 sequence, which could improve safety and transfer less viral sequence into a patient's DNA.

Indexed as

Genome, ViralTransduction, GeneticGenetic VectorsHEK293 CellsHIV-1Humans

Identifiers

PMID34103612
PMCPMC8187449
OpenAlexW3128358567

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.